As malaria continues to remain a major public health challenge in much of the world, the loss of effective and affordable antimalarials through resistance development in malaria parasites is a continuing grave concern. With the parasite genome sequence at hand, there is a renewed hope that a reasonable drug pipeline can be established for dealing with these challenges. A critical goal of basic molecular and cell biological research on malaria parasites is to explore appropriate targets for developing new antimalarials. Our group has previously identified and validated the parasite mitochondrion as an attractive target for antimalarial drugs. Mechanisms of action and resistance to one of the currently used drugs, atovaquone, were elucidated by work in this group. A new class of compounds being developed also appears to target mitochondrial physiology in malaria parasites with related but distinct mode of action from that for atovaquone. One of the aims for the renewed project will be to investigate this series of compounds to derive useful mechanistic details that could aid in further drug development. Biochemical and genomic insights provided by recent work suggest that the parasite mitochondrion is physiologically quite distinct from its host's organelle. For the renewed project, a series of approaches will be taken to understand roles played by some of the canonical mitochondrial processes in different stages of malaria parasite life cycle. Through improved gene disruption methods, some of the questions of long standing regarding the role of the mitochondrion in malaria parasite biology will be addressed. A surprising finding has been the ability of malaria parasites to survive for significant length of time even with inhibited mitochondrial electron transport and collapsed mitochondrial membrane electropotential. Work to be conducted in the renewed project will address mechanisms by which parasites are killed by anti-mitochondrial drugs. Overall, research to be conducted during the next funding period will aim to advance the underlying goals of this project: to derive a deeper understanding of the functional significance the mitochondrion in malaria parasites and the mechanisms by which interference with the mitochondrial functioning leads to parasite demise. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028398-19
Application #
7429809
Study Section
Special Emphasis Panel (ZRG1-PTHE-K (01))
Program Officer
Rogers, Martin J
Project Start
1989-07-01
Project End
2011-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
19
Fiscal Year
2008
Total Cost
$357,207
Indirect Cost
Name
Drexel University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Vaidya, Akhil B (2018) Reflections on an inflection: From virology to parasitology guided by POLARIS. PLoS Pathog 14:e1006941
Ke, Hangjun; Dass, Swati; Morrisey, Joanne M et al. (2018) The mitochondrial ribosomal protein L13 is critical for the structural and functional integrity of the mitochondrion in Plasmodium falciparum. J Biol Chem 293:8128-8137
Ke, Hangjun; Morrisey, Joanne M; Qu, Shiwei et al. (2017) Caged Garcinia Xanthones, a Novel Chemical Scaffold with Potent Antimalarial Activity. Antimicrob Agents Chemother 61:
Frueh, Lisa; Li, Yuexin; Mather, Michael W et al. (2017) Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria. ACS Infect Dis 3:728-735
Bushell, Ellen; Gomes, Ana Rita; Sanderson, Theo et al. (2017) Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Cell 170:260-272.e8
Jenkins, Bethany J; Daly, Thomas M; Morrisey, Joanne M et al. (2016) Characterization of a Plasmodium falciparum Orthologue of the Yeast Ubiquinone-Binding Protein, Coq10p. PLoS One 11:e0152197
Stickles, Allison M; Smilkstein, Martin J; Morrisey, Joanne M et al. (2016) Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother 60:4853-9
Miley, Galen P; Pou, Sovitj; Winter, Rolf et al. (2015) ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob Agents Chemother 59:5555-60
Stickles, Allison M; Ting, Li-Min; Morrisey, Joanne M et al. (2015) Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. Am J Trop Med Hyg 92:1195-201
Ke, Hangjun; Lewis, Ian A; Morrisey, Joanne M et al. (2015) Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle. Cell Rep 11:164-74

Showing the most recent 10 out of 30 publications